Why Sunshine Heart’s Enrollment Issues Are Concerning
Research - Sunshine Heart's (SSH) fourth quarter call was revealing regarding ongoing enrollment problems. Read on to get our take.
PremiumResearch - Sunshine Heart's (SSH) fourth quarter call was revealing regarding ongoing enrollment problems. Read on to get our take.
PremiumInsights - In the Tuesday trading session, shares of Sunshine Heart (SSH) briefly touched and bounced from their 200-day moving average at $7.72. SSH, on which PropThink … Continue Reading
PremiumInsights - On Tuesday at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, Sunshine Heart (SSH) presented updated results from the ongoing OPTIONS-HF European trial testing the … Continue Reading
Read nowLong Ideas - Last week, while most of PropThink’s research team was on vacation, Sunshine Heart (SSH) commenced a secondary offering that should net proceeds of approximately $37 … Continue Reading
Read nowLong Ideas - On Tuesday September 3rd, we hosted an interview and Q&A with Sunshine Heart (SSH) CEO David Rosa; a transcript of the call is available at … Continue Reading
Read nowLong Ideas - Sunshine Heart (SSH) in its quarterly earnings report and conference call on Wednesday provided anecdotal evidence that its C-Pulse device is benefitting late-stage heart failure … Continue Reading
Read nowLong Ideas - With a capital raise recently out of the way and a pivotal trial enrolling towards a regulatory filing in the U.S., Sunshine Heart’s (SSH) $60M … Continue Reading
Read now